GSK Statistics
Total Valuation
GSK has a market cap or net worth of $106.57 billion. The enterprise value is $125.90 billion.
Important Dates
The next estimated earnings date is Wednesday, April 29, 2026, before market open.
| Earnings Date | Apr 29, 2026 |
| Ex-Dividend Date | Feb 20, 2026 |
Share Statistics
GSK has 2.03 billion shares outstanding. The number of shares has decreased by -0.60% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 2.03B |
| Shares Change (YoY) | -0.60% |
| Shares Change (QoQ) | -0.39% |
| Owned by Insiders (%) | 0.05% |
| Owned by Institutions (%) | 86.57% |
| Float | 3.86B |
Valuation Ratios
The trailing PE ratio is 13.85 and the forward PE ratio is 11.16.
| PE Ratio | 13.85 |
| Forward PE | 11.16 |
| PS Ratio | 2.42 |
| Forward PS | 3.10 |
| PB Ratio | 4.96 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 12.42 |
| P/OCF Ratio | 10.23 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 8.25, with an EV/FCF ratio of 14.67.
| EV / Earnings | 16.37 |
| EV / Sales | 2.86 |
| EV / EBITDA | 8.25 |
| EV / EBIT | 9.90 |
| EV / FCF | 14.67 |
Financial Position
The company has a current ratio of 0.82, with a Debt / Equity ratio of 1.11.
| Current Ratio | 0.82 |
| Quick Ratio | 0.50 |
| Debt / Equity | 1.11 |
| Debt / EBITDA | 1.54 |
| Debt / FCF | 2.79 |
| Interest Coverage | 14.36 |
Financial Efficiency
Return on equity (ROE) is 43.31% and return on invested capital (ROIC) is 26.53%.
| Return on Equity (ROE) | 43.31% |
| Return on Assets (ROA) | 9.79% |
| Return on Invested Capital (ROIC) | 26.53% |
| Return on Capital Employed (ROCE) | 23.78% |
| Weighted Average Cost of Capital (WACC) | 5.49% |
| Revenue Per Employee | $657,775 |
| Profits Per Employee | $115,096 |
| Employee Count | 66,841 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 1.54 |
Taxes
In the past 12 months, GSK has paid $1.50 billion in taxes.
| Income Tax | 1.50B |
| Effective Tax Rate | 15.02% |
Stock Price Statistics
The stock price has increased by +29.66% in the last 52 weeks. The beta is 0.32, so GSK's price volatility has been lower than the market average.
| Beta (5Y) | 0.32 |
| 52-Week Price Change | +29.66% |
| 50-Day Moving Average | 54.55 |
| 200-Day Moving Average | 45.60 |
| Relative Strength Index (RSI) | 35.30 |
| Average Volume (20 Days) | 5,141,395 |
Short Selling Information
The latest short interest is 10.81 million, so 0.54% of the outstanding shares have been sold short.
| Short Interest | 10.81M |
| Short Previous Month | 17.72M |
| Short % of Shares Out | 0.54% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.61 |
Income Statement
In the last 12 months, GSK had revenue of $43.97 billion and earned $7.69 billion in profits. Earnings per share was $1.87.
| Revenue | 43.97B |
| Gross Profit | 31.92B |
| Operating Income | 12.71B |
| Pretax Income | 9.96B |
| Net Income | 7.69B |
| EBITDA | 15.26B |
| EBIT | 12.71B |
| Earnings Per Share (EPS) | $1.87 |
Full Income StatementBalance Sheet
The company has $4.60 billion in cash and $23.94 billion in debt, with a net cash position of -$19.34 billion or -$9.50 per share.
| Cash & Cash Equivalents | 4.60B |
| Total Debt | 23.94B |
| Net Cash | -19.34B |
| Net Cash Per Share | -$9.50 |
| Equity (Book Value) | 21.48B |
| Book Value Per Share | 5.49 |
| Working Capital | -5.22B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $10.42 billion and capital expenditures -$1.81 billion, giving a free cash flow of $8.58 billion.
| Operating Cash Flow | 10.42B |
| Capital Expenditures | -1.81B |
| Free Cash Flow | 8.58B |
| FCF Per Share | $4.22 |
Full Cash Flow StatementMargins
Gross margin is 72.61%, with operating and profit margins of 28.92% and 17.50%.
| Gross Margin | 72.61% |
| Operating Margin | 28.92% |
| Pretax Margin | 22.66% |
| Profit Margin | 17.50% |
| EBITDA Margin | 34.70% |
| EBIT Margin | 28.92% |
| FCF Margin | 19.52% |
Dividends & Yields
This stock pays an annual dividend of $1.75, which amounts to a dividend yield of 3.35%.
| Dividend Per Share | $1.75 |
| Dividend Yield | 3.35% |
| Dividend Growth (YoY) | 14.49% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 93.86% |
| Buyback Yield | 0.60% |
| Shareholder Yield | 3.95% |
| Earnings Yield | 7.22% |
| FCF Yield | 8.05% |
Dividend DetailsAnalyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 3.38% |
| EPS Growth Forecast (5Y) | 9.60% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on July 19, 2022. It was a reverse split with a ratio of 1:1.25.
| Last Split Date | Jul 19, 2022 |
| Split Type | Reverse |
| Split Ratio | 1:1.25 |
Scores
GSK has an Altman Z-Score of 2.04 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.04 |
| Piotroski F-Score | 7 |
